Fatigue predicts quality of life after leucine‐rich glioma‐inactivated 1‐antibody encephalitis-Reference-Cited by-同舟云学术

Fatigue predicts quality of life after leucine‐rich glioma‐inactivated 1‐antibody encephalitis

Published:2024-02 Issue: Volume: Page:
ISSN:2328-9503
Container-title:Annals of Clinical and Translational Neurology
language:en
Short-container-title:Ann Clin Transl Neurol

Author:

Binks Sophie N. M.¹²,Veldsman Michele³,Handel Adam E.¹²,Jacob Saiju⁴,Maddison Paul⁵,Coebergh Jan⁶,Michael Sophia¹⁴,Ramanathan Sudarshini¹⁷⁸,Easton Ava⁹¹⁰,Nissen Mette Scheller¹¹¹²,Leite Maria Isabel¹²,Okai David¹³,Blaabjerg Morten¹¹¹²^ORCID,Husain Masud³¹⁴,Irani Sarosh R.¹²¹⁵^ORCID

Affiliation:

1. Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences Oxford UK

2. Department of Neurology Oxford University Hospitals NHS Foundation Trust Oxford UK

3. Department of Experimental Psychology University of Oxford Oxford UK

4. Department of Neurology, Queen Elizabeth Hospital University Hospitals Birmingham NHS Foundation Trust Birmingham UK

5. Department of Neurology, Queen's Medical Centre Nottingham University Hospitals NHS Trust Nottingham UK

6. St Peter's Hospital Ashford and St Peter's NHS Hospitals Foundation Trust Chertsey UK

7. Translational Neuroimmunology Group, Faculty of Medicine and Health University of Sydney Sydney New South Wales Australia

8. Department of Neurology Concord Hospital Sydney New South Wales Australia

9. The Encephalitis Society 32 Castlegate, Malton North Yorkshire YO17 7DT UK

10. Department of Clinical Infection, Microbiology and Immunology University of Liverpool Liverpool UK

11. Department of Neurology Odense University Hospital Odense Denmark

12. Department of Clinical Research University of Southern Denmark Odense DK‐5000 Denmark

13. Neuropsychiatry Department Maudsley Outpatients, Maudsley Hospital Denmark Hill London SE5 8AZ UK

14. Nuffield Department of Clinical Neurosciences Oxford UK

15. Departments of Neurology and Neurosciences Mayo Clinic Jacksonville Florida USA

Abstract

AbstractPatient‐reported quality‐of‐life (QoL) and carer impacts are not reported after leucine‐rich glioma‐inactivated 1‐antibody encephalitis (LGI1‐Ab‐E). From 60 patients, 85% (51 out of 60) showed one abnormal score across QoL assessments and 11 multimodal validated questionnaires. Compared to the premorbid state, QoL significantly deteriorated (p < 0.001) and, at a median of 41 months, fatigue was its most important predictor (p = 0.025). In total, 51% (26 out of 51) of carers reported significant burden. An abbreviated five‐item battery explained most variance in QoL. Wide‐ranging impacts post‐LGI1‐Ab‐E include decreased QoL and high caregiver strain. We identify a rapid method to capture QoL in routine clinic or clinical trial settings.

Funder

National Health and Medical Research Council

Petre Foundation

Medical Research Council

British Medical Association

Epilepsy Research UK

Royal Australasian College of Physicians

University of Sydney

US-UK Fulbright Commission

NIHR Oxford Biomedical Research Centre

National Institute for Health and Care Research

Wellcome Trust

Publisher

Wiley

Subject

Neurology (clinical),General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/acn3.52006

Reference15 articles.

1. Antibodies to Kv1 potassium channel‐complex proteins leucine‐rich, glioma inactivated 1 protein and contactin‐associated protein‐2 in limbic encephalitis;Irani SR;Morvan's Syndrome and Acquired Neuromyotonia Brain,2010

2. The importance of early immunotherapy in patients with faciobrachial dystonic seizures

3. Residual Fatigue and Cognitive Deficits in Patients After Leucine-Rich Glioma-Inactivated 1 Antibody Encephalitis

4. Evaluation of Cognitive Deficits and Structural Hippocampal Damage in Encephalitis With Leucine-Rich, Glioma-Inactivated 1 Antibodies